Pharmaceutical Medicine, Biotechnology and European Law

Description

European law has been faced with increasingly complex issues emerging from rapid developments in pharmaceutical medicine and biotechnology. A team of distinguished European legal practitioners and academics reassess the impact of European law on health care and pharmaceutical law. The essays are grouped under four themes: Free movement of goods and persons, competition and intellectual property; European drug regulation; Biotechnology; and Product liability and transnational health care litigation. The book reviews the impact of European law on movement of health care professionals and pharmaceuticals, patent and trademark rights, the Product Liability Directive, laws on product liability and intellectual property claims. It examines recent developments in drug regulation, particularly data protection, abridged applications for marketing authorisations and the European Medicines Evaluation Agency. A compelling analysis is made of the Biotechnology Directive morality clauses. This important study offers a valuable resource for the pharmaceutical and biotechnology industries, legal academics and practitioners alike.

Dr Richard Goldberg is a Solicitor and Lecturer in Law at the Faculty of Law of the University of Birmingham. He is the author of Causation and Risk in the Law of Torts: Scientific Evidence and Medicinal Product Liability, nominated for the SPTL Book Prize in 1999. Dr Julian Lonbay is Senior Lecturer and Director of the Institute of European Law of the University of Birmingham. His publications include Training Lawyers in the European Community, International Professional Practice, Remedies for Breach of EC Law (edited with Biondi), Enhancing the Legal Position of the European Consumer, and Frontiers of Competition Law

'This important study offers a valuable resource for the pharmaceutical and biotechnology industries, legal academics and practitioners alike. It is up-to-date, well researched and presented, and gives an intriguing overview of some of the most pressing issues on the pharmaceutical and biotechnological scene in modern-day Europe.' Maastricht Journal of European and Comparative Law